Drug Profile
AZD 7009
Latest Information Update: 22 Mar 2007
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Class IV antiarrhythmics
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 01 Feb 2007 Discontinued - Phase-II for Atrial fibrillation in Europe (IV)
- 01 Feb 2007 Discontinued - Phase-II for Atrial fibrillation in USA (IV)
- 09 Feb 2006 Discontinued - Phase-II for Atrial fibrillation in Europe (PO)